Your Health, We Care
Elacestrant is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.
from FDA，2023.05
Elacestrant, an estrogen receptor antagonist developed by the Italian company Me···【more】
Release date：2026-03-16Recommended：52
Elacestrant is an estrogen receptor antagonist developed by the Italian company ···【more】
Release date：2026-03-16Recommended：55
Elacestrant is suitable for the treatment of specific types of breast cancer.【more】
Release date：2026-01-05Recommended：78
LuciusVersionofElacestrant:DosageandAdministration,Indications,PrecautionsIndica···【more】
Release date：2025-12-03Recommended：155
